Talha A. Malik

Gastroenterology

13400 E Shea Blvd
Scottsdale, AZ 85259

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Coccidioidomycosis in patients with inflammatory bowel disease receiving advanced therapy: An observational study from an endemic tertiary center.

Coccidioidomycosis in patients with inflammatory bowel disease receiving advanced therapy: An observational study from an endemic tertiary center.

Journal: Inflammatory bowel diseases

Published: June 09, 2026

Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-based Study.

Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-based Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: March 27, 2026

Advanced Medical Therapies for Perianal Fistulizing Crohn's Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes.

Advanced Medical Therapies for Perianal Fistulizing Crohn's Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 09, 2026

Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis.

Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis.

Journal: Digestive diseases and sciences

Published: January 24, 2026

Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.

Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 06, 2025

Acute Severe Ulcerative Colitis (ASUC): Clinical Features, Initial Management, and the Role of Advanced Therapies.

Acute Severe Ulcerative Colitis (ASUC): Clinical Features, Initial Management, and the Role of Advanced Therapies.

Journal: Biomedicines

Published: September 20, 2025

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor.

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor.

Journal: Biomedicines

Published: August 27, 2025

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East.

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East.

Journal: Crohn's & colitis 360

Published: July 14, 2025

Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.

Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.

Journal: Digestive diseases and sciences

Published: July 02, 2025

The Role of Diet in Crohn's Disease: From Etiology to Evidence-Based Management.

The Role of Diet in Crohn's Disease: From Etiology to Evidence-Based Management.

Journal: Cureus

Published: June 27, 2025

The Unusual Clinical Presentation of Eosinophilic Gastroenteritis and Its Response to Mepolizumab: Two Case Reports.

The Unusual Clinical Presentation of Eosinophilic Gastroenteritis and Its Response to Mepolizumab: Two Case Reports.

Journal: Cureus

Published: October 28, 2024

Risankizumab Is Effective for the Management of Crohn's Disease of the Pouch.

Risankizumab Is Effective for the Management of Crohn's Disease of the Pouch.

Journal: Inflammatory bowel diseases

Published: October 22, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026